0001127602-22-022782.txt : 20220921 0001127602-22-022782.hdr.sgml : 20220921 20220921165059 ACCESSION NUMBER: 0001127602-22-022782 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220919 FILED AS OF DATE: 20220921 DATE AS OF CHANGE: 20220921 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Basil Michelle L CENTRAL INDEX KEY: 0001699629 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-14041 FILM NUMBER: 221256822 MAIL ADDRESS: STREET 1: HAEMONETICS CORPORATION STREET 2: 400 WOOD ROAD CITY: BRAINTREE STATE: MA ZIP: 02184 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: HAEMONETICS CORP CENTRAL INDEX KEY: 0000313143 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 042882273 STATE OF INCORPORATION: MA FISCAL YEAR END: 0401 BUSINESS ADDRESS: STREET 1: 125 SUMMER STREET CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: 7818487100 MAIL ADDRESS: STREET 1: 125 SUMMER STREET CITY: BOSTON STATE: MA ZIP: 02110 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2022-09-19 0000313143 HAEMONETICS CORP HAE 0001699629 Basil Michelle L 125 SUMMER STREET BOSTON MA 02110 1 EVP and General Counsel Common Stock 2022-09-19 4 M 0 3464 38.43 A 38859 D Common Stock 2022-09-19 4 M 0 4213 41.64 A 43072 D Common Stock 2022-09-19 4 M 0 1011 56.57 A 44083 D Common Stock 2022-09-19 4 S 0 11448 78.36 D 32635 D Non-qualified Stock Option (Right to Buy) 38.43 2022-09-19 4 M 0 3464 0 D 2018-03-06 2024-03-06 Common Stock 3464 0 D Non-qualified Stock Option (Right to Buy) 41.64 2022-09-19 4 M 0 4213 0 D 2018-06-06 2024-06-06 Common Stock 4213 0 D Non-qualified Stock Option (Right to Buy) 56.57 2022-09-19 4 M 0 1011 0 D 2028-05-18 Common Stock 1011 12553 D Transaction pursuant to an existing 10b5-1 trading plan. This number includes unvested restricted stock units ("RSUs") previously reported. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.00 to $78.75, inclusive. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. /s/ Michelle L. Basil 2022-09-21